The RIGHT protein and the case for cryo-EM with Proteros
The RIGHT protein and the case for cryo-EM with Proteros
In the fast-evolving landscape of drug discovery, structure-based drug design (SBDD) stands as a cornerstone. Specifically, cryo-electron microscopy (cryo-EM) has showcased tremendous utility within SBDD. Cryo-EM SBDD has enabled rational drug design for targets that were previously considered intractable. However, the development and maintenance of an in-house cryo-EM platform are beyond the reach of most biotech firms, making the selection of the ideal Contract Research Organization (CRO) a pivotal decision. Proteros, based in Munich, Germany, stands out in this arena, aiming to elevate structure throughput, enhance resolution, expedite timelines, and optimize cost-per-structure, thereby truly democratizing structure-based drug design for all target-based drug discovery endeavors. Highlighted ahead are the distinctive strengths and unique attributes that cement Proteros’ position at the forefront of the industry, setting us apart as a pioneering force in SBDD.
The primacy of protein in cryo-EM
Just as ‘location, location, location’ is the mantra in real estate, in the realm of cryo-EM it’s all about ‘protein, protein, protein’. The challenge is magnified by the nature of proteins typically targeted by cryo-EM, many of which are notoriously difficult to produce. This is where our strength at Proteros shines. At Proteros, we specialize in tackling the ‘high hanging fruit’ proteins that pose the greatest challenges in the industry. With a formidable team of over 100 PhD-trained protein scientists and experience spanning tens of thousands of protein constructs, we’re equipped to handle these intricate proteins. Our dedication to accelerating drug discovery is evident in our commitment to establish Gallery Structures, an initiative designed to cut down on timelines and costs. The Gallery Structures for cryo-EM at Proteros expedite the process due to our extensive experience with these systems, coupled with established methodologies, protocols, and SOPs. This foundation enables the rapid determination of high-resolution repeat structures with customer-specific ligands, typically achieved within a few weeks and at competitive rates. The recent establishment of GLP1R as a Gallery Structure serves as a testament to this effort. With our deep expertise, Proteros is poised to be the go-to solution for intricate structures, be it membrane proteins (such as GPCRs, ion channels, solute carriers), small targets, or large multi-subunit complexes.
Offering an industrialized cryo-EM service from one hand
Having made significant strides in the industrialization of protein crystallography, we’re now channeling our efforts to shape the future of cryo-EM. At the heart of our approach is the aspiration to unravel even the most intricate of structures. This requires not only selecting the apt protein but also leveraging state-of-the-art cryo-EM technology and our deep-rooted expertise. Our cryo-EM team, with its diverse skill set, specializes in project evaluation and customization in line with specific client requirements. They work diligently to meet set goals in a timely manner. A key advantage is that Proteros’ in-house protein and cryo-EM platforms can operate in tandem, providing dynamic insights that inform and drive sample optimization. This integrated approach encapsulates our commitment to delivering an end-to-end, streamlined cryo-EM experience. Furthermore, Proteros acknowledges the synergistic potential of integrating both cryo-EM and crystallography. Specifically, while cryo-EM can guide construct design for crystallography, it also complements the process by providing insights into protein dynamics and revealing transient states that may be elusive in crystallographic systems.
Europe offers low costs and political stability
As a leading structure-based drug discovery CRO, we pride ourselves on offering a streamlined experience for our global clientele. When clients provide a protein name, we take care of the rest, right up to delivering the atomic coordinates. Operating from Europe positions us advantageously, allowing us to present solutions that are both cost-effective, aligning well with the typically constrained budgets of structural biology, and stable. In a world grappling with political flux, the consistent stability of Europe offers the assurance that drug discovery programs and biotech investors value deeply.
All of the news, delivered with full-text to your inbox. For professionals discovering, developing, and marketing biopharmaceutical drugs.
Accelerate your discovery with our holistic approach
In conclusion, Proteros is poised to elevate the horizons of what can be achieved with cryo-EM in drug discovery. Our capabilities span a broad spectrum of structures and modalities, ensuring that whether it’s membrane proteins, small targets, multi-subunit complexes, targeted protein degradation, gene therapy, antibody discovery, or small molecule discovery, we’ve got it covered. And Proteros not only excels in cryo-EM services but also provides a holistic approach to drug discovery through its Discovery Solutions. By integrating every essential component of the discovery process, from the RIGHT protein selection, advanced structural biology, and customized assay development to a diverse range of screening library options and comprehensive biophysical mode-of-action methodologies, Proteros ensures that no stone is left unturned in the pursuit of potential hit compounds.
To learn more about Proteros and how we can accelerate your drug discovery initiatives, reach out to us. Our team of experts is eager to collaborate and drive your projects to fruition.
